Pharmacogenetics and pharmagenomics, trends in normal and pathological aging studies: Focus on p53

Current Pharmaceutical Design

Volumn 14, Issue 26, 2008, Pages 2665-2671

  Lanni, C ^a,b   Racchi, M ^a,b   Uberti, D ^b   Mazzini, G ^a   Stanga, S ^a,b   Memo, M ^c   Memo, E ^b   Govoni, S ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Aging; Alzheimer's disease; Beta amyloid; Biomarker; Conformationally altered p53; Pharmacogenetics; Pharmacogenomics

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CELL CYCLE PROTEIN; DONEPEZIL; PRESENILIN; PROTEIN P53;

AGING; ALZHEIMER DISEASE; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL FATE; DEMENTIA; DNA DAMAGE; DOSE RESPONSE; DRUG METABOLISM; GENETIC VARIABILITY; HUMAN; LONGEVITY; MALIGNANT NEOPLASTIC DISEASE; NERVE CELL PLASTICITY; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN TERTIARY STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOPTOSIS; FEMALE; HUMANS; MALE; MUTATION; NEURONAL PLASTICITY; PHARMACOGENETICS; PROTEIN STRUCTURE, TERTIARY; SYNAPSES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 57349167712     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786264133     Document Type: Review

References (66)

1. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-37.
2. Guay DR. Geriatric pharmacotherapy updates. Am J Geriatr Pharmacother 2008; 6: 37-48.
3. Bowie MW, Slattum PW. Pharmacodynamics in older adults: A review. Am J Geriatr Pharmacother 2007; 5: 263-303.
4. El Desoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther 2007; 14: 488-98.
5. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.
6. Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 2008; 8: 4-15.
7. Varsaldi F, Miglio G, Scordo MG, Dahl ML, Villa LM, Biolcati A, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol 2006; 62: 721-6.
8. Cacabelos R, Fernandez-Novoa L, Lombardi V, Kubota Y, Takeda M. Molecular genetics of Alzheimer's disease and aging. Methods Find Exp Clin Pharmacol 2005; 27(Suppl A): 1-573.
9. Grimaldi MP, Vasto S, Balistreri CR, di Carlo D, Caruso M, Incalcaterra E, et al. Genetics of inflammation in age-related atherosclerosis: its relevance to pharmacogenomics. Ann N Y Acad Sci 2007; 1100: 123-31.
10. Martin GM, Bergman A, Barzilai N. Genetic determinants of human health span and life span: Progress and new opportunities. PLoS Genet 2007; 3: e125.
11. Martin GM. Genetic and evolutionary aspects of aging. Feder Proc 1979; 38: 1962-7.
12. Martin GM. Genetics and the pathobiology of ageing. Philos Trans R Soc Lond B Biol Sci 1997; 352: 1773-80.
13. Perls T, Terry D. Genetics of exceptional longevity. Exp Gerontol 2003; 38: 725-30.
14. Schächter F, Cohen D, Kirkwood T. Prospects for the genetics of human longevity. Hum Genet 1993; 91: 519-26.
15. Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569-73.
16. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, et al. p53 mutant mice that display early ageingassociated phenotypes. Nature 2002; 415: 45-53.
17. Cacabelos R, Takeda M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease. Drugs Future 2006; 31(Suppl B): 5-146.
18. Schächter F, Faure-Delanef L, Gunot F, Rouger H, Froguel P, Lesueur-Ginot L, et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994; 6: 29-32.
19. Perls T, Terry D. Genetics of exceptional longevity. Exp Gerontol 2003; 38: 725-30.
20. Perls T, Terry D. Understanding the determinants of exceptional longevity. Ann Intern Med 2003; 139(5 Pt 2): 445-9.
21. Roses AD, Burns DK, Chissoe S, Middleton L, St Jean P. Diseasespecific target selection: A critical first step down the right road. Drug Discov Today 2005; 10: 177-89.
22. Cupples LA, Arruda HT, Benjamin EJ, D'Agostino RB Sr, Demissie S, DeStefano AL, et al. The Framingham Heart Study 100K SNP genome-wide association study resource: Overview of 17 phenotype working group reports. BMC Med Genet 2007; 8(Suppl 1): S1.
23. Perls T, Puca A. The genetics of aging-- implications for pharmacogenomics. Pharmacogenomics 2002; 3: 469-84.
24. Palmer LJ, Cardon LR. Shaking the tree: Mapping complex disease genes with linkage disequilibrium. Lancet 2005; 366: 1223-34.
25. Cullen LM, Arndt GM. Genome-wide screening for gene function using RNAi in mammalian cells. Immunol Cell Biol 2005; 83: 217-23.
26. Saunders AM, Trowers MK, Shimkets RA, Blakemore S, Crowther DJ, Mansfield TA et al. The role of apolipoprotein E in Alzheimer's disease: Pharmacogenomic target selection. Biochim Biophys Acta 2000; 1502: 85-94.
27. Roses AD, Pangalos MN. Drug development and Alzheimer disease. Am J Geriatr Psychiatry 2003; 11: 123-30.
28. Roses AD, Saunders AM. Perspective on a pathogenesis and treatment of Alzheimer's disease. Alzheimer's Dementia 2006; 2: 59-70.
29. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-62.
30. Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 2002; 3: 67-99.
31. http://www.ncbi.nlm.nih.gov/OMIM
32. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006; 314: 777-81.
33. Suh Y-H, Checler F. Amyloid precursor protein, presenilins, and asynuclein: Molecular pathogenesis and pharmacological applications in Alzheimer's disease. Phamacol Rev 2002; 54: 469-525.
34. Rodier F, Campisi J, Bhaumik D. Two faces of p53: Aging and tumor suppression. Nucleic Acids Res 2007; 35: 7475-84.
35. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
36. Sager R. Senescence as a mode of tumor suppression. Environ Health Perspect 1991; 93: 59-62.
37. Sionov RV, Haupt Y. The cellular response to p53: The decision between life and death. Oncogene 1999; 18: 6145-57.
38. Ljungman M. Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress. Neoplasia 2000; 2: 208-25.
39. Meulmeester E, Jochemsen AG. p53: A guide to apoptosis. Curr Cancer Drug Targets 2008; 8: 87-97.
40. Jänicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: Anti-apoptotic p53. Cell Death Differ 2008; 15: 959-76.
41. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007; 26: 7773-9.
42. Chao C, Saito S, Kang J, Anderson CW, Appella E, Xu Y. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J 2000; 19: 4967-75.
43. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268: 2764-72.
44. Colman MS, Afshari CA, Barrett JC. Regulation of p53 stability and activity in response to genotoxic stress. Mutat Res 2000; 462: 179-88.
45. Bakkenist CJ, Kastan MB. Initiating cellular stress responses. Cell 2004; 118: 9-17.
46. Al Rashid ST, Dellaire G, Cuddihy A, Jalali F, Vaid M, Coackley C, et al. Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Res 2005; 65: 10810-21.
47. Guillouf C, Graña X, Selvakumaran M, De Luca A, Giordano A, Hoffman B, et al. Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: Blocking p53-induced apoptosis unmasks G1 arrest. Blood 1995; 85: 2691-8.
48. Shawi M, Autexier C. Telomerase, senescence and ageing. Mech Ageing Dev 2008; 129: 3-10.
49. Donehower LA. Does p53 affect organismal aging? J Cell Physiol 2002; 192: 23-33.
50. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 2000; 60: 6788-93.
51. Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 2001; 21: 2661-8.
52. Uberti D, Lanni C, Carsana T, Francisconi S, Missale C, Racchi M, et al. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol Aging 2006; 27: 1193-201.
53. Lanni C, Racchi M, Mazzini G, Ranzenigo A, Polotti R, Sinforiani E, et al. Conformationally altered p53: A novel Alzheimer's disease marker? Mol Psychiatry 2008; 13: 641-7.
54. Govoni S, Gasparini L, Racchi M, Trabucchi M. Peripheral cells as an investigational tool for Alzheimer's disease. Life Sci 1996; 59: 461-8.
55. Gasparini L, Racchi M, Binetti G, Trabucchi M, Solerte SB, Alkon D, et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J 1998; 12: 17-34.
56. Lanni C, Uberti D, Racchi M, Govoni S, Memo M. Unfolded p53: A potential biomarker for Alzheimer's disease. J Alzheimers Dis 2007; 12: 93-9.
57. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004; 1: 213-25.
58. Blennow K. CSF biomarkers for Alzheimer's disease: Use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 2005; 5: 661-72.
59. Di Luca M, Pastorino L, Bianchetti A, Perez J, Vignolo LA, Lenzi GL, et al. Differential level of platelet amyloid beta precursor protein isoforms: An early marker for Alzheimer disease. Arch Neurol 1998; 55: 1195-200.
60. Tang K., Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: A bio-marker for Alzheimer's disease. J Neurol Sci 2006; 240: 53-8.
61. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-8.
62. Francisconi S, Codenotti M, Ferrari-Toninelli G, Uberti D, Memo M. Preservation of DNA integrity and neuronal degeneration. Brain Res Brain Res Rev 2005; 48: 347-51.
63. Copani A, Uberti D, Sortino MA, Bruno V, Nicoletti F, Memo M. Activation of cell-cycle-associated proteins in neuronal death: A mandatory or dispensable path? Trends Neurosi 2001; 24: 25-31.
64. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des 2008; 14(14): 1419-27.
65. Silva MT, do Vale A, dos Santos NM. Fish and apoptosis: Studies in disease and pharmaceutical design. Curr Pharm Des 2008; 14(2): 170-83.
66. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008; 14(10): 973-8.